A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
Your participation in this trial could last up to 12 months, depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have a cancer that did not respond to standard therapy and has spread to another part(s) of the body
-Participant must be willing to have new tumor tissue biopsies (doctor removes a small amount of tissue) during the study as long as it does not cause undue risks to health
-Participant must be willing to use highly effective birth control
-Participant must not have certain infections such as hepatitis or tuberculosis or HIV that is not well controlled or received certain types of vaccines in the last 30 days
-Participant must not have moderate to severe heart disease or heart problems as a result of exposure to certain chemotherapy
-Participant must not have cancer of the central nervous system that is not stable
-Participant must not have certain diseases that affect immune system, such as autoimmune vasculitis
-Participant must not use high doses or increasing doses of corticosteroids or other drugs to suppress the immune system
-Participant must not have disorders of the bowel such as bowel blockage, inflammation of the bowel, surgical removal of large parts of the bowel, or evidence of certain types of lung disease or inflammation
-Participant must not be pregnant or breastfeeding